Effects of Nordic Walking in Water on Cerebrovascular Function and Cognitive Impairment in Elderly With Type 2 Diabetes
NCT05641090, Not applicable, Unknown, Chulalongkorn University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Nordic Walking in Water on Cerebrovascular Function and Cognitive Impairment in Elderly With Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT05641090 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 36 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Chulalongkorn University | ClinicalTrials.gov |
| Conditions | Elderly With Type 2 Diabetes | ClinicalTrials.gov |
| Interventions | Nordic walking in water, No exercise intervention | ClinicalTrials.gov |
| First posted | 2022-12-07 | ClinicalTrials.gov |
| Last updated | 2022-12-07 | ClinicalTrials.gov |
Registered outcomes 26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | General physiological data | Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks. | 1.Blood pressure in mmHg will be measured with automated blood pressure device (CARESCAPE V100, GE Dinamap). | ClinicalTrials.gov |
| Primary | Heart rate | Change from baseline heart rate at 12 weeks. | Heart rate in beats per minute will be measured with automated blood pressure device (CARESCAPE V100, GE Dinamap). | ClinicalTrials.gov |
| Primary | ฺBody fat | Change from baseline body fat at 12 weeks. | Body fat in percent will be measured with dual energy x-ray absorptiometry (Prodigy-Pro, GE healthcare). | ClinicalTrials.gov |
| Primary | Muscle mass and Weight | Change from baseline muscle mass and weight at 12 weeks. | Muscle mass and weight in kilograms will be measured with dual energy x-ray absorptiometry (Prodigy-Pro, GE healthcare). | ClinicalTrials.gov |
| Primary | Arterial stiffness | Change from baseline brachial-ankle pulse wave velocity at 12 weeks. | Arterial stiffness will be measured with brachial-ankle pulse wave velocity in centimeter per second (VP-1000 plus, omrom Healthcare). | ClinicalTrials.gov |
| Primary | Macro vascular function | Change from baseline brachial artery flow-mediated dilatation at 12 weeks. | Macro vascular function will be measured by brachial artery flow-mediated dilatation in percent with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Cerebral blood flow | Change from baseline cerebral blood flow at 12 weeks. | Cerebral blood flow in centimeter per second will be measured with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Cerebrovascular conductance index | Change from baseline cerebrovascular conductance index at 12 weeks. | Cerebrovascular conductance index in cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Cerebrovascular reactivity index | Change from baseline cerebrovascular reactivity index at 12 weeks. | Cerebrovascular reactivity index in %cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Arterial compliance | Change from baseline Arterial compliance at 12 weeks. | Arterial compliance in units will be measure by carotid diameter during systolic and diastolic with ultrasonography equipment (EPIQ 5G, Phillips) and systemic blood pressure with (VP-1000 plus, omrom Healthcare). | ClinicalTrials.gov |
| Primary | Pulsatility index | Change from baseline Pulsatility index at 12 weeks. | Pulsatility index in units will be measure with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment | Change from baseline Montreal Cognitive Assessment at 12 weeks. | Montreal Cognitive Assessment in score (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function. | ClinicalTrials.gov |
| Primary | Mini-Mental State Examination | Change from baseline Mini-Mental State Examination at 12 weeks. | Mini-Mental State Examination in scores (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function. | ClinicalTrials.gov |
| Primary | Trail Making Test-B and Stroop test | Change from baseline Trail Making Test-B and Stroop test at 12 weeks. | Trail Making Test-B in second cut off below 101 seconds that indicate dementia. Stroop test in second will be measured with EncephalApp Stroop test. | ClinicalTrials.gov |
| Secondary | Waist circumference | Change from baseline waist circumference at 12 weeks | Waist circumference in centimeters will be measure by waist tape | ClinicalTrials.gov |
| Secondary | Flexibility testing | Change from baseline Chair sit & reach and Back scratch at 12 weeks. | Flexibility testing will be measure by Chair sit \& reach protocol and Back scratch in centimeters. | ClinicalTrials.gov |
| Secondary | Muscle strength testing | Change from baseline arm-curl and chair stand at 12 weeks. | Muscle strength testing will be measured by arm-curl test and chair stand test in repetitions in 30 seconds. | ClinicalTrials.gov |
| Secondary | Balance testing | Change from baseline time up and go at 12 weeks. | Balance testing will be measured by time up and go testing in seconds. | ClinicalTrials.gov |
| Secondary | Cardiopulmonary fitness | Change from baseline 2-minutes step at 12 weeks. | Cardiopulmonary fitness will be measure by 2-minutes step test in repetitions. | ClinicalTrials.gov |
| Secondary | Cardiopulmonary fitness | Change from baseline 6-minutes walk at 12 weeks. | Cardiopulmonary fitness will be measure by 6-minutes walk test in meters. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)